Leveraging Translational & Biomarker Research to Improve Patient Stratification, Enable Earlier Decision-Making & Accelerate Liver Fibrosis Drug Development

• Generating deeper insights into disease progression and treatment response through integrated biomarker approaches to better characterize patient populations, enabling more informed development strategies and improving trial precision
• Leveraging exploratory biomarker readouts to improve decision-making, reducing development risk and accelerating program progression
• Aligning biomarker strategies with regulatory and clinical endpoints to strengthen translational confidence, improving development efficiency and supporting future adoption of non-invasive approaches

Speakers:

Jen-Chieh (Jay) Chuang

Global Program Lead & Translational Medicine, Biomarker Lead, Liver diseases

Takeda